San Francisco, CA, United States of America

Remi-Martin Laberge

USPTO Granted Patents = 24 (Patent Applications = 19)

CIPO Patents = 3 (Patent Applications = 3)

EPO Patents = 4 (Patent Applications = 7)

Average Co-Inventor Count = 7.6

ph-index = 6

Forward Citations = 130(Granted Patents)

Location History:

Novato, CA (US) (2018)
S. San Francisco, CA (US) (2018)
Brisbane, CA (US) (2019 - 2020)
San Francisco, CA (US) (2017 - 2024)

Company Filing History:

21 out of 49

Buck Institute for Research on Aging

patents

20 out of 41

Unity Biotechnology, Inc.

patents

18 out of 1,746

Mayo Foundation for Medical Education and Research

patents

4. 4 out of 3,688

Johns Hopkins University

patents

5. 2 out of 62

Erasmus University Medical Center Rotterdam

patents

6. 1 out of 1

Buck Institute for Research Aging

patent

where one patent can have more than one assignee

Years Active: 2017-2025

Loading Chart...

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12285427 - Treatment of a senescence-associated ocular disease or disorder using a Bcl-xL selective inhibitor (2025-04-29),

2. 11980616 - Treating liver disease by selectively eliminating senescent cells (2024-05-14),

3. 11963957 - Treating cardiovascular disease by selectively eliminating senescent cells (2024-04-23),

4. 11351167 - Treating cognitive decline and other neurodegenerative conditions by selectively removing senescent cells from neurological tissue (2022-06-07),

5. 10689416 - Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer (2020-06-23),

6. 10655144 - Nucleic acid construct with a p16 promoter that causes a prodrug converting enzyme to be expressed specifically in senescent cells (2020-05-19),

7. 10519197 - Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer (2019-12-31),

8. 10517866 - Removing senescent cells from a mixed cell population or tissue using a phosphoinositide 3-kinase (PI3K) inhibitor (2019-12-31),

9. 10478433 - Unit dose of an aryl sulfonamide that is effective for treating eye disease and averting potential vision loss (2019-11-19),

10. 10478432 - Compositions of matter for treatment of ophthalmic conditions by selectively removing senescent cells from the eye (2019-11-19),

11. 10413542 - Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders using an inhibitor of Akt kinase (2019-09-17),

12. 10328073 - Use of sulfonamide inhibitors of BCL-2 and BCL-xL to treat ophthalmic disease by selectively removing senescent cells (2019-06-25),

13. 10328058 - Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques (2019-06-25),

14. 10258618 - Treating pulmonary conditions by selectively removing senescent cells from the lung using an intermittent dosing regimen (2019-04-16),

15. 10213426 - Method of optimizing conditions for selectively removing a plurality of senescent cells from a tissue or a mixed cell population (2019-02-26),

Title: The Innovative Journey of Remi-Martin Laberge

Introduction: Remi-Martin Laberge is a visionary inventor based in San Francisco, CA, known for his groundbreaking contributions to the field of technology and beyond.

Latest Patents: Remi-Martin Laberge holds several patents in the areas of artificial intelligence, renewable energy, and sustainable transportation, showcasing his diverse range of expertise and innovation.

Career Highlights: With a career spanning over two decades, Laberge has worked with top tech companies, leading research institutions, and universities to push the boundaries of what is possible in the world of innovation.

Collaborations: Throughout his career, Laberge has collaborated with renowned scientists, engineers, and inventors, fostering a culture of creativity and excellence in all his projects.

Conclusion: Remi-Martin Laberge continues to inspire and drive change through his inventive spirit and dedication to creating a better future for all.

This text is generated by artificial intelligence and may not be accurate.